Tuesday reported third-quarter earnings of 27 cents a share, beating the 25-cent
First Call/Thomson Financial
estimate and last year's 21 cents.
Third-quarter revenue came in at $7.2 billion, a 7% gain over the previous year. Sales of the company's drugs, which include the cholesterol fighter Lipitor, anti-arthritis treatment Celebrex and the much-joked-about Viagra, rose 12% during the quarter.
Pfizer also said full-year earnings would meet analysts' expectations, but the company forecast a $1 billion reduction in revenue, stemming from currency weakness and other factors. Pfizer said full-year revenue would come in at $30 billion.